의료진 상세정보 보기 로그인

눈문/저서

  1. [2018] New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients (Korean J Intern Med)
  2. [2017] Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD (ANNALS OF HEMATOLOGY)
  3. [2016] Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes (ANNALS OF HEMATOLOGY)
  4. [2016] Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia. (Blood res)
  5. [2015] Survey of expert opinions and related recommendations regarding bridging therapy using hypomethylating agents followed by allogeneic transplantation for high-risk MDS (CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY)
  6. [2015] Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Monosomal Karyotypes (ACTA HAEMATOLOGICA)
  7. [2015] 만성골수성백혈병 한국 치료 가이드라인-대한혈액학회 (대한내과학회지)
  8. [2015] Favorable Effects of Low-Dose Anti-Thymocyte Globulin in a Partially-Mismatched HLA Group in an Unrelated Allogeneic Stem Cell Transplantation Setting (ANNALS OF TRANSPLANTATION)
  9. [2014] Is a cure for CML without allogeneic stem cell transplantation around the corner? (Blood Res. 2014 Sep;49(3):141-3)
  10. [2014] Adoptable strategic approaches to improve outcomes of allogeneic peripheral blood stem cell transplantations from unrelated donors (TRANSFUSION)
  11. [2013] When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents? (EXPERT REVIEW OF HEMATOLOGY)
  12. [2013] Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement (CANCER RESEARCH AND TREATMENT)
  13. [2013] Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate (INTERNATIONAL JOURNAL OF HEMATOLOGY)
  14. [2013] Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era (ANNALS OF HEMATOLOGY)
  15. [2012] Absolute lymphocyte count at day+21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (LEUKEMIA LYMPHOMA)
  16. [2012] Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients (MEDICAL ONCOLOGY)
  17. [2012] Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy (Kor J Int Med)
  18. [2012] Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast (ANNALS OF HEMATOLOGY)
  19. [2011] Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia (Acta haematol)
  20. [2011] Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML (전남의대학술지)
  21. [2011] Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia (LEUKEMIA LYMPHOMA)
  22. [2010] Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset (BONE MARROW TRANSPLANTATION)
  23. [2010] Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors (ANNALS OF HEMATOLOGY)
  24. [2010] Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment (ANNALS OF HEMATOLOGY)
  25. [2010] Pre-Emptive Treatment with Nilotinib after Second Allogeneic Transplantation in a Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patient with High Risk of Relapse (ACTA HAEMATOLOGICA)
  26. [2010] Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP (CANCER CHEMOTHERAPY AND PHARMACOLOGY)
  27. [2009] Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review (INTERNATIONAL JOURNAL OF HEMATOLOGY)
  28. [2009] Mobilization Effects of G-CSF, GM-CSF, and Darbepoetin-alpha for Allogeneic Peripheral Blood Stem Cell Transplantation (JOURNAL OF CLINICAL APHERESIS)
  29. [2009] Clinical Significance of Autoantibody Expression in Allogeneic Stem-Cell Recipients (TRANSPLANTATION)
  30. [2009] Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients (BONE MARROW TRANSPLANTATION)
  31. [2009] 미만성 거대 B세포 림프종 환자 치료 후 절대림프구수 감소율의 예후적 의의 (대한내과학회지)
  32. [2008] Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors (AMERICAN JOURNAL OF HEMATOLOGY)
  33. [2006] The association between multidrug resistance-1 gene polymorphisms and outcomes of allogeneic HLA-identical stem cell transplantation (HAEMATOLOGICA-THE HEMATOLOGY JOURNAL)
  34. [2005] 급성 골수성 백혈병의 효율적 치료를 위한 맞춤 치료 및 이식 전략 (대한내과학회지)